Details for Patent: 8,716,251
✉ Email this page to a colleague
Which drugs does patent 8,716,251 protect, and when does it expire?
Patent 8,716,251 protects QTERNMET XR, FARXIGA, and QTERN, and is included in three NDAs.
This patent has fifty-seven patent family members in twenty-six countries.
Summary for Patent: 8,716,251
Title: | Pharmaceutical formulations containing an SGLT2 inhibitor |
Abstract: | Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate ##STR00001## and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release. |
Inventor(s): | Bindra; Dilbir S. (New Brunswick, NJ), Dali; Mandar V. (Bridgewater, NJ), Parab; Prakash V. (New Brunswick, NJ), Patel; Jatin M. (New Brunswick, NJ), Tao; Li (New Brunswick, NJ), Tejwani; Ravindra W. (New Brunswick, NJ), Vatsaraj; Nipa (New Brunswick, NJ), Wu; Yongmei (New Brunswick, NJ) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 13/734,655 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,716,251 |
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 8,716,251
International Family Members for US Patent 8,716,251
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 065809 | ⤷ Try a Trial | |||
Australia | 2008228714 | ⤷ Try a Trial | |||
Brazil | 122017015098 | ⤷ Try a Trial | |||
Brazil | PI0809233 | ⤷ Try a Trial | |||
Canada | 2681526 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |